Blueblood Ventures

₹11.1 0 | 0%

WEBSITE BSE:539637 NSE : BVL 29 May, 00:00

Market Cap ₹3 Cr.

Stock P/E

P/B -0.7

Current Price ₹11.1

Book Value ₹ -16.6

Face Value 10

52W High ₹11.1

Dividend Yield 0%

52W Low ₹ 11.1

Edit Ratio

Blueblood Ventures Research see more...

Overview Inc. Year: 2007Industry: Finance - Stock Broking

Blueblood Ventures Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Blueblood Ventures Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Blueblood Ventures Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Net Sales	0	0	3	1	3	60	1	2	0	1	0
Other Income	0	0	0	0	0	0	0	0	0	0	0
Total Income	1	0	3	1	3	60	1	2	0	1	0
Total Expenditure	1	-0	0	-10	-2	55	1	5	1	1	0
Operating Profit	0	0	3	11	4	5	-0	-3	-1	0	0
Interest	0	0	3	11	4	3	0	0	0	0	0
Depreciation	0	0	0	0	0	1	0	0	0	0	0
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	0	0	0	0	0	0	-0	-3	-1	0	0
Provision for Tax	0	0	0	0	0	0	0	0	0	0	0
Profit After Tax	0	0	0	0	0	0	-0	-3	-1	0	0
Adjustments	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	0	0	0	0	0	0	-0	-3	-1	0	0
Adjusted Earnings Per Share	0.7	0.3	0.6	0.4	0.7	1	-0.7	-9.5	-2.2	0.1	0.1

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-100%	-100%	-100%	0%
Operating Profit CAGR	0%	0%	-100%	0%
PAT CAGR	0%	0%	0%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	26%	6%	3%	NA%
ROE Average	0%	0%	-500%	-227%
ROCE Average	0%	-0%	-1%	2%

Blueblood Ventures Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	4	6	8	15	15	16	6	3	3	3	3
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	5	7	37	100	115	132	94	94	94	94	94
Other Non-Current Liabilities	0	-0	-0	-0	-0	-0	-0	0	0	0	0
Total Current Liabilities	2	3	18	22	28	7	2	2	1	0	0
Total Liabilities	11	17	63	138	158	155	102	99	98	97	97
Fixed Assets	0	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	6	139	90	88	87	87	82
Total Current Assets	10	16	63	137	152	5	2	3	3	3	7
Total Assets	11	17	63	138	158	155	102	99	98	97	97

Blueblood Ventures Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	1	5	1	0	0	0	0	0	0	0
Cash Flow from Operating Activities	1	-1	-34	-60	-5	130	-11	-6	-1	-1	-1
Cash Flow from Investing Activities	1	1	1	0	-6	0	49	6	1	1	1
Cash Flow from Financing Activities	-1	5	29	59	10	-130	-38	-0	-0	-0	-0
Net Cash Inflow / Outflow	1	4	-4	-0	-0	-0	0	0	-0	-0	0
Closing Cash & Cash Equivalent	1	5	1	0	0	0	0	0	0	0	0

Blueblood Ventures Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	0.69	0.29	0.57	0.41	0.68	1.01	-0.71	-9.49	-2.21	0.07	0.06
CEPS(Rs)	0.77	0.49	0.75	0.54	0.78	3.71	-0.63	-9.45	-2.19	0.08	0.18
DPS(Rs)	0	0	0	0	0	0	0	0	0	0	0
Book NAV/Share(Rs)	49.49	50	50.3	50.31	50.85	15.45	-15.4	-17.08	-16.69	-16.62	-19.16
Core EBITDA Margin(%)	-30.7	0	89.16	1725.34	166.03	7.34	-54.61	-128.12	-140.9	-0.89	-32.82
EBIT Margin(%)	40.92	0	99.4	1741.59	170.78	6.21	-29.18	-121.34	-142.28	3.21	17
Pre Tax Margin(%)	17.44	0	4.21	29.16	11.27	0.68	-36.51	-122.16	-142.75	3.19	16.46
PAT Margin (%)	12.1	0	3.22	20.04	7.96	0.51	-36.77	-129.64	-142.75	3.19	16.46
Cash Profit Margin (%)	13.4	0	4.27	25.96	9.12	1.87	-33.01	-129.1	-141.35	3.65	49.64
ROA(%)	0.5	0.28	0.23	0.12	0.14	0.19	-0.17	-2.83	-0.67	0.02	0.02
ROE(%)	1.41	0.74	1.25	1.08	1.35	3.03	-2501.87	0	0	0	0
ROCE(%)	1.92	0.53	9.49	13.47	3.23	2.48	-0.15	-2.98	-0.74	0.02	0.02
Receivable days	1899.29	0	167.16	5.13	0	0	0	295.19	1403.05	1008.24	0
Inventory Days	341.62	0	3822.32	0	0	447.95	403.08	89.53	293.66	151.48	710.53
Payable days	1018.24	-1778.58	0	-3.58	-10.49	1.59	205.6	56.15	579.68	86.53	-661.81
PER(x)	0	0	0	86.89	61.5	30.33	0	0	0	152.9	0
Price/Book(x)	0	0	0	0.72	0.83	1.97	-0.82	0	-0.55	-0.63	0
Dividend Yield(%)	0	0	0	0	0	0	0	0	0	0	0
EV/Net Sales(x)	9.83	0	13.22	178.67	60	2.45	170.03	44.17	208.42	149.73	876.74
EV/Core EBITDA(x)	23.29	29.58	13.16	10.22	34.9	32.4	-669.08	-36.56	-147.94	4082.36	1747.16
Net Sales Growth(%)	8.87	-100	0	-77.93	314.76	2218.54	-99.03	280.9	-78.86	39.76	-82.96
EBIT Growth(%)	717.27	-65.94	4581.56	286.71	-59.33	-15.63	-104.54	-1484.13	75.21	103.15	-9.62
PAT Growth(%)	1063.2	-26.91	138.79	37.39	64.84	47.25	-170.25	-1242.84	76.72	103.12	-12.08
EPS Growth(%)	1063.2	-57.63	93.85	-27.02	64.83	47.26	-170.24	-1242.85	76.72	103.12	-12.17
Debt/Equity(x)	1.33	1.12	4.63	6.64	9.3	29.61	-20.4	-18.34	-18.77	-18.84	-16.35
Current Ratio(x)	5.3	5.65	3.55	6.15	5.4	0.69	1.01	1.73	2.61	9.66	19.75
Quick Ratio(x)	5	5.28	0.27	0.22	0.23	0.61	0.55	1.52	2.27	9.1	18.99
Interest Cover(x)	1.74	0	1.04	1.02	1.07	1.12	-3.98	-147.94	-300.27	208	31.33
Total Debt/Mcap(x)	0	0	0	9.27	11.26	15	24.92	0	33.86	29.69	0

Blueblood Ventures Shareholding Pattern

#	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024
Promoter	53.12	53.12	53.12	53.12	53.12	53.12	53.12	53.12	53.12	53.12
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	46.88	46.88	46.88	46.88	46.88	46.88	46.88	46.88	46.88	46.88
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024
Promoter	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14
Others	0	0	0	0	0	0	0	0	0	0
Total	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

Pros

Stock is trading at -0.7 times its book value
Debtor days have improved from 86.53 to -661.81days.
Company is almost debt free.

Cons

Company has a low return on equity of 0% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.